RNS Number : 2055U MaxCyte, Inc. 27 June 2024 Publication of Annual Report ROCKVILLE, MD , June 27, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and
RNS Number : 4058S MaxCyte, Inc. 14 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and Restricted Stock Units ROCKVILLE, MD , June 14, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 0511S MaxCyte, Inc. 12 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Results of AGM Rockville, Maryland - June 12 , 2024: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 9400R MaxCyte, Inc. 11 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") PDMR Dealing ROCKVILLE, MD , June 12, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,
RNS Number : 9173Q MaxCyte, Inc. 03 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights and Block Listing Return ROCKVILLE, MD , June 3, 2024 : MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 2809Q MaxCyte, Inc. 29 May 2024 MaxCyte to Participate in William Blair 44 th Annual Growth Stock Conference Rockville, MD , May 29, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 4603P MaxCyte, Inc. 22 May 2024 4867-2449-5548v.1 MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development Legend Biotech obtains license to use MaxCyte's Flow Electroporation® technology and
RNS Number : 0054P MaxCyte, Inc. 20 May 2024 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting
RNS Number : 4093O MaxCyte, Inc. 14 May 2024 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting
RNS Number : 5010N MaxCyte, Inc. 08 May 2024 MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2024 ROCKVILLE, MD , May 8, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
